Trial Profile
A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) and Nivolumab in Patients With MDS or Low Blast Count AML
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Nivolumab (Primary) ; Poly ICLC (Primary) ; Rasdegafusp-alfa (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 04 Oct 2021 Status changed from active, no longer recruiting to completed.
- 29 Dec 2020 Planned End Date changed from 13 Dec 2020 to 25 Aug 2021.